Nj State Employees Deferred Compensation Plan Clovis Oncology, Inc. Transaction History

Nj State Employees Deferred Compensation Plan

$824 Million
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 01, 2019	SELL	$17.66 - $30.28 $17,660 - $30,280	-1,000 Reduced 7.14%	13,000 $323,000
Q3 2018 Oct 16, 2018	BUY	$29.37 - $49.48 $29,370 - $49,480	1,000 Added 7.69%	14,000 $411,000
Q2 2018 Aug 02, 2018	BUY	$42.06 - $62.4 $84,120 - $124,800	2,000 Added 18.18%	13,000 $591,000
Q1 2018 May 02, 2018	BUY	$50.12 - $67.72 $100,240 - $135,440	2,000 Added 22.22%	11,000 $581,000
Q3 2017 Oct 30, 2017	BUY	$67.17 - $84.81 $604,530 - $763,290	9,000	9,000 $742,000

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nj State Employees Deferred Compensation Plan, based on Form 13F filings with the SEC.

News

Stay updated on Nj State Employees Deferred Compensation Plan with notifications on news.

Account